141 related articles for article (PubMed ID: 26110200)
1. Discovery and Optimization of a Porcupine Inhibitor.
Duraiswamy AJ; Lee MA; Madan B; Ang SH; Tan ES; Cheong WW; Ke Z; Pendharkar V; Ding LJ; Chew YS; Manoharan V; Sangthongpitag K; Alam J; Poulsen A; Ho SY; Virshup DM; Keller TH
J Med Chem; 2015 Aug; 58(15):5889-99. PubMed ID: 26110200
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer.
Proffitt KD; Madan B; Ke Z; Pendharkar V; Ding L; Lee MA; Hannoush RN; Virshup DM
Cancer Res; 2013 Jan; 73(2):502-7. PubMed ID: 23188502
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
Xu Z; Li J; Wu Y; Sun Z; Luo L; Hu Z; He S; Zheng J; Zhang H; Zhang X
Eur J Med Chem; 2016 Jan; 108():154-165. PubMed ID: 26647303
[TBL] [Abstract][Full Text] [Related]
4. The development of highly potent inhibitors for porcupine.
Wang X; Moon J; Dodge ME; Pan X; Zhang L; Hanson JM; Tuladhar R; Ma Z; Shi H; Williams NS; Amatruda JF; Carroll TJ; Lum L; Chen C
J Med Chem; 2013 Mar; 56(6):2700-4. PubMed ID: 23477365
[TBL] [Abstract][Full Text] [Related]
5. The use of porcupine inhibitors to target Wnt-driven cancers.
Ho SY; Keller TH
Bioorg Med Chem Lett; 2015 Dec; 25(23):5472-6. PubMed ID: 26522946
[TBL] [Abstract][Full Text] [Related]
6. Development of a triazole class of highly potent Porcn inhibitors.
You L; Zhang C; Yarravarapu N; Morlock L; Wang X; Zhang L; Williams NS; Lum L; Chen C
Bioorg Med Chem Lett; 2016 Dec; 26(24):5891-5895. PubMed ID: 27876319
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective fatty acylation is essential for the release of lipidated WNT proteins from the acyltransferase Porcupine (PORCN).
Tuladhar R; Yarravarapu N; Ma Y; Zhang C; Herbert J; Kim J; Chen C; Lum L
J Biol Chem; 2019 Apr; 294(16):6273-6282. PubMed ID: 30737280
[TBL] [Abstract][Full Text] [Related]
8. An
Asciolla JJ; Miele MM; Hendrickson RC; Resh MD
J Biol Chem; 2017 Aug; 292(33):13507-13513. PubMed ID: 28655768
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the linkage elements of porcupine antagonists led to potent Wnt signaling pathway inhibitors.
Dong Y; Li K; Xu Z; Ma H; Zheng J; Hu Z; He S; Wu Y; Sun Z; Luo L; Li J; Zhang H; Zhang X
Bioorg Med Chem; 2015 Nov; 23(21):6855-68. PubMed ID: 26455655
[TBL] [Abstract][Full Text] [Related]
10. Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine
Rao DM; Shackleford MT; Bordeaux EK; Sottnik JL; Ferguson RL; Yamamoto TM; Wellberg EA; Bitler BG; Sikora MJ
J Biol Chem; 2019 Dec; 294(52):19950-19966. PubMed ID: 31740580
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Liu J; Pan S; Hsieh MH; Ng N; Sun F; Wang T; Kasibhatla S; Schuller AG; Li AG; Cheng D; Li J; Tompkins C; Pferdekamper A; Steffy A; Cheng J; Kowal C; Phung V; Guo G; Wang Y; Graham MP; Flynn S; Brenner JC; Li C; Villarroel MC; Schultz PG; Wu X; McNamara P; Sellers WR; Petruzzelli L; Boral AL; Seidel HM; McLaughlin ME; Che J; Carey TE; Vanasse G; Harris JL
Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20224-9. PubMed ID: 24277854
[TBL] [Abstract][Full Text] [Related]
12. Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers.
Yang Q; Qin T; An T; Wu H; Xu G; Xiang J; Lei K; Zhang S; Xia J; Su G; Wang D; Xue M; Kong L; Zhang W; Wu S; Li Y
Eur J Pharmacol; 2023 Apr; 945():175628. PubMed ID: 36858339
[TBL] [Abstract][Full Text] [Related]
13. Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine.
Dodge ME; Moon J; Tuladhar R; Lu J; Jacob LS; Zhang LS; Shi H; Wang X; Moro E; Mongera A; Argenton F; Karner CM; Carroll TJ; Chen C; Amatruda JF; Lum L
J Biol Chem; 2012 Jun; 287(27):23246-54. PubMed ID: 22593577
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design.
Poulsen A; Ho SY; Wang W; Alam J; Jeyaraj DA; Ang SH; Tan ES; Lin GR; Cheong VW; Ke Z; Lee MA; Keller TH
J Chem Inf Model; 2015 Jul; 55(7):1435-48. PubMed ID: 26024410
[TBL] [Abstract][Full Text] [Related]
15.
Lee CJ; Rana MS; Bae C; Li Y; Banerjee A
J Biol Chem; 2019 Jan; 294(1):231-245. PubMed ID: 30420431
[TBL] [Abstract][Full Text] [Related]
16. Precise regulation of porcupine activity is required for physiological Wnt signaling.
Proffitt KD; Virshup DM
J Biol Chem; 2012 Oct; 287(41):34167-78. PubMed ID: 22888000
[TBL] [Abstract][Full Text] [Related]
17. Porcupine Inhibitor LGK974 Downregulates the Wnt Signaling Pathway and Inhibits Clear Cell Renal Cell Carcinoma.
Li J; Wu G; Xu Y; Li J; Ruan N; Chen Y; Zhang Q; Xia Q
Biomed Res Int; 2020; 2020():2527643. PubMed ID: 32104684
[TBL] [Abstract][Full Text] [Related]
18. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
Shah K; Panchal S; Patel B
Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
[TBL] [Abstract][Full Text] [Related]
19. Identification of key residues and regions important for porcupine-mediated Wnt acylation.
Rios-Esteves J; Haugen B; Resh MD
J Biol Chem; 2014 Jun; 289(24):17009-19. PubMed ID: 24798332
[TBL] [Abstract][Full Text] [Related]
20. Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis.
Madan B; Patel MB; Zhang J; Bunte RM; Rudemiller NP; Griffiths R; Virshup DM; Crowley SD
Kidney Int; 2016 May; 89(5):1062-1074. PubMed ID: 27083283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]